Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study

被引：2
|
作者：
Strati, Paolo [1 ]
Champion, Rebecca [2 ]
Coleman, Morton [3 ]
Smith, Sonali M. [4 ]
Venugopal, Parameswaran [5 ]
Martin, Peter [6 ]
Wood, Andrew [7 ]
Miller, Kara [8 ]
Christian, Beth [9 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Norton Canc Inst, Louisville, KY USA
[3] Weill Cornell Med, Clin Res Alliance, New York, NY USA
[4] Univ Chicago, Med Ctr, Chicago, IL USA
[5] Rush Univ, Med Ctr, Chicago, IL USA
[6] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA
[7] AstraZeneca, Cambridge, England
[8] AstraZeneca, South San Francisco, CA USA
[9] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2024年 / 205卷 / 06期
关键词：
B-cell lymphoma; Bruton tyrosine kinase; non-Hodgkin lymphoma; TYROSINE KINASE INHIBITOR; B-CELLS; IBRUTINIB; ACP-196;
D O I：
10.1111/bjh.19787
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Acalabrutinib is a selective, second-generation Bruton tyrosine kinase inhibitor. In this open-label, parallel-group study, patients with relapsed/refractory (R/R) follicular lymphoma (FL) were randomised to either acalabrutinib monotherapy or acalabrutinib plus rituximab. An additional cohort of patients with treatment-naive (TN) FL received only the acalabrutinib-rituximab combination. Acalabrutinib-rituximab was well tolerated and active in R/R and TN FL; in the TN cohort the overall response rate was 92.3% with most remissions lasting over 4 years. Acalabrutinib monotherapy was also well tolerated and active in R/R FL. These results support further study of acalabrutinib alone and in combination with rituximab in FL.
引用
收藏
页码：2248 / 2253
页数：6
相关论文
共 50 条
  • [1] Acalabrutinib alone or in combination with rituximab (R) in follicular lymphoma (FL).
    Fowler, Nathan Hale
    Coleman, Morton
    Stevens, Don A.
    Smith, Sonali M.
    Venugopal, Parameswaran
    Martin, Peter
    Phillips, Tycel Jovelle
    Agajanian, Richy
    Stephens, Deborah Marie
    Izumi, Raquel
    Cheung, Jean
    Slatter, J. Greg
    Yin, Ming
    Hiremath, Minoti
    Hunder, Naomi N. H.
    Christian, Beth
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] A Phase 2, Open-Label, Multicenter Study of Tazemetostat in Combination with Rituximab for the Treatment of Relapsed or Refractory Follicular Lymphoma
    Patel, Krish
    Bailey, Neil
    Pagel, John M.
    BLOOD, 2020, 136
  • [3] Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003)
    Strati, Paolo
    Agajanian, Richy
    Lossos, Izidore S.
    Coleman, Morton
    Kridel, Robert
    Wood, Andrew
    Lesley, Robin
    Wun, Chuan-Chuan
    Stephens, Deborah M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2025, 206 (03) : 887 - 898
  • [4] Traverse: A Phase 2, Open-Label, Randomized Study of Acalabrutinib in Combination with Venetoclax and Rituximab in Patients with Treatment-Naive Mantle Cell Lymphoma
    Hawkes, Eliza A.
    Fletcher, Rachel
    Wood, Andrew
    Meyer, Stefanie
    Rule, Simon
    Zhang, Jingyang
    Wang, Michael L.
    BLOOD, 2023, 142
  • [5] High Complete Response Rates with Pembrolizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: Results of an Open-Label, Phase II Study
    Nastoupil, Loretta
    Westin, Jason R.
    Fowler, Nathan H.
    Fanale, Michelle A.
    Samaniego, Felipe
    Oki, Yasuhiro
    Dsouza, Ly
    Obi, Chizobam
    Cao, JingJing
    Cheng, Xiaoyun
    Ma, Man Chun John
    Wang Zhiqiang
    Feng, Lei
    Zhou, Shouhao
    Davis, R. Eric
    Neelapu, Sattva S.
    BLOOD, 2017, 130
  • [6] High Complete Response Rates With Pembrolizumab in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma: Results of an Open-Label, Phase II Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 14 - 15
  • [7] Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: Interim results of an on open-label, phase II study.
    Nastoupil, Loretta J.
    Westin, Jason R.
    Fowler, Nathan Hale
    Fanale, Michelle A.
    Samaniego, Felipe
    Oki, Yasuhiro
    Obi, Chizobam
    Cao, JingJing
    Cheng, Xiaoyun
    Ma, Man Chun John
    Wang, Zhigiang
    Chu, Fuliang
    Feng, Lei
    Zhou, Shouhao
    Davis, Richard Eric
    Neelapu, Sattva Swarup
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] High Complete Response Rates With Pembrolizumab in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma: Results of an Open-Label, Phase 2 Study
    Martin, Peter
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (04) : 6 - 7
  • [9] Acrue: A Phase 2, Open-Label Study of Acalabrutinib in Combination with Rituximab in Elderly and/or Frail Patients with Treatment-Naive Diffuse Large B-Cell Lymphoma
    Perini, Guilherme F.
    Graff, Tara
    Roos, Jack
    Hermann, Richard
    Lovenklev, Magnus
    Shaw, Bob
    Budde, L. Elizabeth
    BLOOD, 2023, 142
  • [10] ACRUE: A Phase 2, Open-Label Study of Acalabrutinib in Combination With Rituximab in Elderly and/or Frail Patients With Treatment-Naive Diffuse Large B- Cell Lymphoma
    Perini, Guilherme F.
    Graff, Tara
    Roos, Jack
    Hermann, Richard
    Lovenklev, Magnus
    Shaw, Bob
    Budde, Lihua E.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S462 - S462
12345